What is Hypervision Surgical?
Hypervision Surgical is at the forefront of medical technology, pioneering the use of hyperspectral imaging to enhance surgical procedures. Its proprietary Hyperspectral Intelligence® platform combines advanced spectral sensing with patented AI analytics. This technology provides surgeons with quantitative tissue insights that surpass the limitations of human vision, paving the way for the next generation of intelligent surgical imaging systems. As a spin-out from Kings College London, the company leverages deep academic research and development to bring cutting-edge solutions to the operating room.
How much funding has Hypervision Surgical raised?
Hypervision Surgical has raised a total of $30.7M across 2 funding rounds:
Angel/Seed
$7.8M
Series A
$22.9M
Angel/Seed (2023): $7.8M with participation from Heran Partners, LifeX Ventures, and Redalpine
Series A (2026): $22.9M led by Angelini Ventures, ZEISS, Heran Partners, SAGES Ingenuity, Redalpine, and LifeX Ventures
Key Investors in Hypervision Surgical
Angelini Ventures
Angelini Ventures is a venture capital firm that invests in BioTech and HealthTech companies, focusing on transforming healthcare through technology. They aim to improve patient journeys and address unmet needs in vulnerable populations.
ZEISS
ZEISS is an international technology enterprise operating in the fields of optics and optoelectronics, developing and distributing a wide range of advanced technology products including medical technology.
Heran Partners
Heran Partners is a Belgium-based venture capital investor focused on creating transformative impacts in the healthcare and life sciences sectors, investing in innovative companies with strong scientific and entrepreneurial capabilities.
What's next for Hypervision Surgical?
With the recent major strategic investment, Hypervision Surgical is poised to scale its operations and further develop its groundbreaking Hyperspectral Intelligence® platform. The company's focus on quantitative tissue insights through AI-driven hyperspectral imaging suggests a strategic direction towards enhancing surgical precision, improving patient outcomes, and potentially reducing healthcare costs. Future developments are likely to involve expanding clinical applications, securing regulatory approvals, and forging strategic partnerships within the global healthcare ecosystem. The enterprise-level funding indicates a transition towards broader market adoption and commercialization.
See full Hypervision Surgical company page
